Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer of the skin, known as nodules. As a result of the itching, some people also ...

The FDA approved Nemluvio in the form of a prefilled pen for subcutaneous injection for the treatment of prurigo nodularis in adults, Galderma announced in a press release.“The U.S. FDA’s ...

The Business Research Company's Prurigo Nodularis Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores ...

Nemolizumab was well tolerated in the long-term treatment of prurigo nodularis, and this study identified no new safety signals.

Prurigo nodularis is a serious skin condition characterized by several debilitating symptoms, including chronic itch, skin nodules covering large body areas, and poor sleep quality. 5-7,10 The ...

The Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis.

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, according to results from a long-term extension ...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.